Emcure Pharmaceuticals Ltd's Q3FY25 Quarter Results
- 07 Feb 2025
Result Summary
- Emcure Pharmaceuticals Ltd reported a 3.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.9%.
- Its expenses for the quarter were down by 1.6% QoQ and up 14.3% YoY.
- The net profit decreased 22.6% QoQ and increased 30.3% YoY.
- The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 8.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1966.53 | 2037.64 | 1696.58 | -3.5% | 15.9% |
Total Expenses | 1736.61 | 1764.23 | 1518.95 | -1.6% | 14.3% |
Profit Before Tax | 229.92 | 273.41 | 170.96 | -15.9% | 34.5% |
Tax | 73.83 | 71.86 | 51.20 | 2.7% | 44.2% |
Profit After Tax | 156.09 | 201.55 | 119.75 | -22.6% | 30.3% |
Earnings Per Share | 8.10 | 10.30 | 0.00 | -21.4% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company that specializes in the development, manufacture, and marketing of a broad range of pharmaceutical products. The company is involved in the production of formulations, active pharmaceutical ingredients (APIs), and biotechnology products. Emcure operates within the pharmaceutical industry, which is characterized by rapid innovation and regulatory compliance. As of my last update, Emcure has been actively expanding its global footprint and strengthening its research and development capabilities to enhance product offerings and market reach. However, specific recent developments beyond this period are not available.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Emcure Pharmaceuticals Ltd reported a total income of ₹1966.53 crores. This represents a quarter-over-quarter (QoQ) decrease of 3.5% from the second quarter of the fiscal year 2025 (Q2FY25), where the total income was ₹2037.64 crores. On a year-over-year (YoY) basis, the total income increased by 15.9% compared to the third quarter of the fiscal year 2024 (Q3FY24), which stood at ₹1696.58 crores. This indicates a significant growth in revenue over the year, despite the quarterly decline.
Profitability
Emcure Pharmaceuticals Ltd's profit before tax for Q3FY25 was ₹229.92 crores, reflecting a 15.9% decrease from Q2FY25's profit before tax of ₹273.41 crores. However, when compared to Q3FY24, there was a notable increase of 34.5% from ₹170.96 crores. The tax expense for Q3FY25 amounted to ₹73.83 crores, which is a slight increase of 2.7% from the previous quarter and a substantial rise of 44.2% from the same quarter last year. Consequently, the profit after tax for Q3FY25 was ₹156.09 crores, down by 22.6% QoQ from ₹201.55 crores, but up by 30.3% YoY from ₹119.75 crores. The earnings per share for Q3FY25 were ₹8.10, a decrease of 21.4% from Q2FY25.
Operating Metrics
The total expenses for Emcure Pharmaceuticals Ltd in Q3FY25 were ₹1736.61 crores, marking a reduction of 1.6% QoQ from ₹1764.23 crores in Q2FY25. On a YoY basis, total expenses increased by 14.3% from ₹1518.95 crores in Q3FY24. This trend indicates a careful management of operating costs despite the revenue fluctuations observed. While the data does not provide specific ratios like the P/E ratio, debt-to-equity ratio, or current ratio, the reported earnings and expenses highlight key financial dynamics affecting the company's operational efficiency and profitability.
